References
- Kolansky G. Cyclosporine formulary considerations. Pharmacy Ther 1992; 17: 494–504
- McCrea JB, et al. The beneficial effects of isradipine on renal hemodynamics in cyclosporine-treated renal transplant recipients. Transplantation 1993; 55: 672–74
- Sandimmun package insert. Sandoz, East Hanover, NJ June, 1986
- McCrea J B, Francos G F, Burke JF, et al. TDx Immunosuppressant Drug Assays Cyclosporine and Metabolites Whole Blood, package insert, no. 9840–60. Abbott Laboratories, Abbott Park, Ill. 1992
- Endresen L, Bergan S, Holdaas H, et al. Lack of effect of the calcium antagonist isradipine on Cyclosporine pharmacokinetics in renal transplant patients. Ther Drug Monit 1991; 13: 490–5
- Martinez F, Pirson Y, Wallemacq P, et al. No clinically significant interaction between Cyclosporine and isradipine. Nephron 1991; 59: 658–9
- Yee G C, McGuire TR. Pharmacokinetic drug interactions with Cyclosporine (part 1). Clin Pharmacokinet 1990; 19: 319–32
- Brosen K. Cytokrom P450 gen-superfamiliens betydning for laegemidlers kliniske farmakokinetik. (The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs.). Ugeskr Laeger 1991; 153(6)417–22